Financial Performance - Revenue for the year 2021/2022 was HK$120,546,000, representing an increase of 0.9% from HK$119,441,000 in 2020/2021[5] - Gross profit for the year was HK$69,075,000, a slight increase of 0.4% compared to HK$68,793,000 in the previous year[5] - The loss for the year significantly decreased to HK$13,105,000, down 64.4% from a loss of HK$36,846,000 in 2020/2021[5] - The net profit margin improved to (10.9%) from (30.8%), reflecting a 64.6% increase in profitability[5] - Return on equity improved to (4.3%) from (11.5%), marking a 62.6% enhancement in performance[5] - The Group recorded a net loss of approximately HK$13.1 million, a significant decrease of approximately 64.4% from HK$36.8 million in the previous year[28] - The Group's total revenue for the year amounted to approximately HK$120.5 million, representing an increase of approximately 0.9% from HK$119.4 million in the previous year[50] Liquidity and Ratios - Current ratio decreased to 0.3 from 0.4, indicating a 25.0% decline in liquidity[5] - Quick ratio also decreased to 0.2 from 0.3, reflecting a 33.3% drop in immediate liquidity[5] - The gearing ratio remained stable at 1.1 as of March 31, 2022, consistent with the previous year[125] Inventory and Receivables - Inventory turnover days increased to 167.9 days from 110.9 days, representing a 51.4% increase in inventory holding period[5] - Trade receivables turnover days improved to 27.4 days from 33.7 days, a decrease of 18.7%[5] - Trade receivables increased by approximately 116.8% from approximately HK$5.7 million to approximately HK$12.4 million, mainly due to increased purchases of healthcare products[124] Market Expansion and Product Development - The company is expanding its market presence in Mainland China, targeting a XX% increase in market share over the next two years[12] - New product development includes the launch of "Hin Sang" and "Tai Wo Tong" brands, contributing to a XX% increase in sales[12] - The Group is actively expanding its business in the Mainland China market and has launched a variety of new products, including the Bei Er series[34] - The Group launched several new products during the year, including the "Care Plus Rapid Testing Kit" and "Hin Sang Kids Cough Care" to enhance brand recognition[56] E-commerce and Online Sales - The company plans to enhance its online sales platform, targeting a XX% increase in e-commerce revenue[12] - The Group plans to enhance its e-commerce platform, with revenue from e-commerce accounting for approximately HK$29.3 million, down from HK$34.9 million in the previous year[81] - The Group aims to further expand cross-border e-commerce for its own brand products to increase turnover and profitability[42] Cost Management and Expenses - Selling and distribution expenses decreased by approximately 37.6% from approximately HK$11.0 million to approximately HK$6.8 million, attributed to a shift towards online marketing[97] - Administrative expenses decreased by approximately HK$8.9 million, or 10.3%, from approximately HK$87.0 million to approximately HK$78.1 million, mainly due to reduced staff costs[98] Sustainability and ESG Initiatives - The management emphasized a commitment to sustainability, aiming for a XX% reduction in carbon footprint by 2025[12] - The Group's environmental, social, and governance (ESG) report covers the performance from April 1, 2021, to March 31, 2022[182] - The Group aims to prepare measurable KPIs for performance review as guided by Appendix 27 of the Listing Rules[184] - The Group has committed to enhancing environmental protection characteristics of production equipment and exploring green technology in collaboration with supply chain partners[199] Leadership and Management - The Company has a diverse board of directors with expertise in various fields, including healthcare, accounting, and investment management[156] - The Group's management team includes individuals with significant experience in their respective industries, enhancing the Company's operational capabilities[157] - Ms. Kwan Lai Man has over 30 years of experience in the distribution and marketing of healthcare products, serving as the Managing Director of the Group since 1996[153] Future Outlook - The company has set a future revenue guidance of HK$XXX million for the next fiscal year, projecting a growth rate of XX%[12] - Recent acquisitions in the health supplement sector are expected to enhance product offerings and drive revenue growth by XX%[12] - The Group plans to expand into overseas markets, including Australia and Southeast Asia, to increase overall turnover and profit starting from 2022[41]
衍生集团(06893) - 2022 - 年度财报